|
|
|
|
|
My Recent Searches
|
|
|
|
|
|
|
Nurix Therapeutics, Inc. (NRIX) |
|
|
$0.00 0.00 (0.00%) as of 4:30 Tue 11/30
|
|
Download |
|
|
|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
47,040,000 |
Market
Cap: |
N/A |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$ - $ |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Nurix Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies designed to modulate cellular protein levels as a treatment approach for cancer and other diseases. Co.'s Bruton's tyrosine kinase (BTK) degrader drug candidates, NX-2127 and NX-5948, are orally available chimeric targeting molecules for the treatment of relapsed or refractory B-cell malignancies and autoimmune indications. Co.'s drug candidate from its E3 ligase inhibitor portfolio, NX-1607, is an orally bioavailable Casitas B-lineage lymphoma proto-oncogene B inhibitor for immuno-oncology indications.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
34,166 |
46,743 |
69,684 |
82,132 |
Total Sell Value |
$602,180 |
$716,467 |
$925,403 |
$1,081,499 |
Total People Sold |
3 |
3 |
3 |
4 |
Total Sell Transactions |
9 |
13 |
21 |
37 |
End Date |
2024-04-07 |
2024-01-05 |
2023-07-07 |
2022-07-07 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Ring Christine |
General Counsel |
|
2021-03-10 |
4 |
AS |
$39.44 |
$82,539 |
D/D |
(2,000) |
805 |
|
- |
|
Ring Christine |
General Counsel |
|
2021-03-10 |
4 |
OE |
$1.86 |
$3,720 |
D/D |
2,000 |
2,805 |
|
- |
|
Beaurang Pierre |
Chief Business Officer |
|
2021-03-08 |
4 |
AS |
$36.48 |
$277,678 |
D/D |
(7,500) |
0 |
|
- |
|
Beaurang Pierre |
Chief Business Officer |
|
2021-03-08 |
4 |
OE |
$0.84 |
$6,300 |
D/D |
7,500 |
7,500 |
|
- |
|
Hansen Gwenn |
Chief Scientific Officer |
|
2021-03-01 |
4 |
AS |
$35.95 |
$28,760 |
D/D |
(800) |
13,804 |
|
- |
|
Hansen Gwenn |
Chief Scientific Officer |
|
2021-03-01 |
4 |
OE |
$7.26 |
$5,808 |
D/D |
800 |
14,604 |
|
- |
|
Van Houte Hans |
Chief Financial Officer |
|
2021-02-24 |
4 |
AS |
$39.90 |
$1,413,218 |
D/D |
(35,419) |
0 |
|
- |
|
Van Houte Hans |
Chief Financial Officer |
|
2021-02-24 |
4 |
OE |
$1.20 |
$62,297 |
D/D |
35,419 |
35,419 |
|
- |
|
Van Houte Hans |
Chief Financial Officer |
|
2021-02-22 |
4 |
AS |
$39.93 |
$212,839 |
D/D |
(5,330) |
0 |
|
- |
|
Van Houte Hans |
Chief Financial Officer |
|
2021-02-22 |
4 |
OE |
$0.84 |
$5,886 |
D/D |
5,330 |
5,330 |
|
- |
|
Beaurang Pierre |
Chief Business Officer |
|
2021-02-18 |
4 |
AS |
$34.19 |
$532,352 |
D/D |
(15,000) |
0 |
|
- |
|
Beaurang Pierre |
Chief Business Officer |
|
2021-02-18 |
4 |
OE |
$0.84 |
$55,275 |
D/D |
15,000 |
15,000 |
|
- |
|
Ring Christine |
General Counsel |
|
2021-02-18 |
4 |
AS |
$34.48 |
$71,750 |
D/D |
(2,000) |
0 |
|
- |
|
Ring Christine |
General Counsel |
|
2021-02-18 |
4 |
OE |
$1.86 |
$3,720 |
D/D |
2,000 |
2,000 |
|
- |
|
Hansen Gwenn |
Chief Scientific Officer |
|
2021-02-18 |
4 |
AS |
$35.81 |
$29,018 |
D/D |
(800) |
12,000 |
|
- |
|
Hansen Gwenn |
Chief Scientific Officer |
|
2021-02-18 |
4 |
OE |
$7.26 |
$5,808 |
D/D |
800 |
12,800 |
|
- |
|
Van Houte Hans |
Chief Financial Officer |
|
2021-02-18 |
4 |
AS |
$34.24 |
$481,621 |
D/D |
(13,583) |
0 |
|
- |
|
Van Houte Hans |
Chief Financial Officer |
|
2021-02-18 |
4 |
OE |
$0.84 |
$11,410 |
D/D |
13,583 |
13,583 |
|
- |
|
Levin Mark J |
10% Owner |
|
2021-02-04 |
4 |
D |
$0.00 |
$0 |
D/D |
(914,216) |
4,508,333 |
|
- |
|
Hansen Gwenn |
Chief Scientific Officer |
|
2020-11-30 |
4 |
OE |
$0.84 |
$10,080 |
D/D |
12,000 |
12,000 |
|
- |
|
Green Jeremy |
10% Owner |
|
2020-07-28 |
4 |
A |
$0.00 |
$0 |
I/I |
1,176,470 |
1,176,470 |
|
- |
|
Wellington Biomedical Innovation Master Investors |
10% Owner |
|
2020-07-28 |
4 |
A |
$0.00 |
$0 |
D/D |
784,313 |
784,313 |
|
- |
|
Goeddel David V |
Managing Partner |
|
2020-07-28 |
4 |
A |
$0.00 |
$0 |
D/D |
6,672,548 |
686,274 |
|
- |
|
Svennilson Peter |
Managing Partner |
|
2020-07-28 |
4 |
A |
$0.00 |
$0 |
D/D |
6,672,548 |
686,274 |
|
- |
|
Tepper Robert I |
10% Owner |
|
2020-07-28 |
4 |
A |
$0.00 |
$0 |
D/D |
5,422,549 |
5,422,549 |
|
- |
|
184 Records found
|
|
Page 7 of 8 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|